Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C: efficacy and safety in real life.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2017

Flisiak Robert, Pogorzelska Joanna, Flisiak-Jackiewicz Marta

Abstract excerpt

Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Coinfection
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrrolidines

Share to Simeprevir

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Valine

Source

Identifiers

PMID: 28052633
DOI: 10.1111/liv.13293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C: efficacy and safety in real life.PMID 28052633Read ↗

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?Semantic proximity Read ↗

Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.Semantic proximity Read ↗

Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.Semantic proximity Read ↗

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.Semantic proximity Read ↗

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.Semantic proximity Read ↗

Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C CohortSemantic proximity Read ↗

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.Semantic proximity Read ↗

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.Semantic proximity Read ↗

Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.Semantic proximity Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.